NASDAQ:OMGA Omega Therapeutics (OMGA) Stock Forecast, Price & News $2.30 +0.05 (+2.22%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$2.14▼$2.3750-Day Range$2.25▼$5.6852-Week Range$2.11▼$11.98Volume73,927 shsAverage Volume122,363 shsMarket Capitalization$126.82 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Omega Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside378.3% Upside$11.00 Price TargetShort InterestBearish10.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.14) to ($2.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 stars 3.5 Analyst's Opinion Consensus RatingOmega Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Omega Therapeutics has a forecasted upside of 378.3% from its current price of $2.30.Amount of Analyst CoverageOmega Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.08% of the float of Omega Therapeutics has been sold short.Short Interest Ratio / Days to CoverOmega Therapeutics has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.Change versus previous monthShort interest in Omega Therapeutics has recently increased by 4.88%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOmega Therapeutics does not currently pay a dividend.Dividend GrowthOmega Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OMGA. Previous Next 2.6 News and Social Media Coverage News SentimentOmega Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Omega Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for OMGA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omega Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.00% of the stock of Omega Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.68% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Omega Therapeutics are expected to decrease in the coming year, from ($2.14) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omega Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Omega Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmega Therapeutics has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Omega Therapeutics (NASDAQ:OMGA) StockOmega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More OMGA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMGA Stock News HeadlinesSeptember 28, 2023 | markets.businessinsider.comPromising Preliminary Data and Novel Mechanism of Omega Therapeutics’ OTX-2002 Bolster Analyst’s Buy RatingSeptember 26, 2023 | markets.businessinsider.comOmega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I TrialSeptember 28, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 26, 2023 | finance.yahoo.comOmega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I TrialSeptember 25, 2023 | finance.yahoo.comOmega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26September 24, 2023 | barrons.comOmega Therapeutics Inc.September 2, 2023 | msn.comHC Wainwright & Co. Reiterates Omega Therapeutics (OMGA) Buy RecommendationAugust 7, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Omega Therapeutics (OMGA)September 28, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 5, 2023 | finance.yahoo.comOmega Therapeutics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsAugust 3, 2023 | finance.yahoo.comOmega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue EstimatesAugust 3, 2023 | finance.yahoo.comOmega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressJuly 20, 2023 | finance.yahoo.comRecursion (RXRX) Stock Surges 191% in 3 Months: Here's WhyJuly 19, 2023 | msn.comApellis (APLS) Stock Surges 62% in 6 Months: Here's WhyJuly 18, 2023 | finance.yahoo.comCorcept's (CORT) Early-Stage Study on NASH Reveals Positive DataJuly 16, 2023 | finance.yahoo.comOMGA - Omega Therapeutics, Inc.July 12, 2023 | uk.news.yahoo.comBristol Myers (BMY) Reports Positive Data From Urothelial Cancer StudyJuly 12, 2023 | msn.comADC Therapeutics (ADCT) Dips on Halting Zynlonta StudyJuly 12, 2023 | finance.yahoo.comOmega Therapeutics Appoints Chris Schade to its Board of DirectorsJune 6, 2023 | msn.comHC Wainwright & Co. Reiterates Omega Therapeutics (OMGA) Prior RecommendationJune 6, 2023 | finance.yahoo.comBellerophon (BLPH) Down 87% as Lung Disease Candidate FailsMay 31, 2023 | finance.yahoo.comAshvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of DirectorsMay 31, 2023 | finance.yahoo.comOmega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual MeetingMay 25, 2023 | finance.yahoo.comWall Street Analysts See a 59.64% Upside in Omega Therapeutics, Inc. (OMGA): Can the Stock Really Move This High?May 25, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Omega Therapeutics (OMGA)May 10, 2023 | seekingalpha.comOmega Therapeutics: 2023 Could Well Be A Turning PointMay 10, 2023 | finance.yahoo.comInvestors in Omega Therapeutics (NASDAQ:OMGA) have seen impressive returns of 177% over the past yearSee More Headlines Receive OMGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OMGA Company Calendar Last Earnings8/03/2023Today9/28/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OMGA CUSIPN/A CIK1850838 Webwww.omegatherapeutics.com Phone617-949-4360FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+378.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,700,000.00 Net Margins-4,283.72% Pretax Margin-4,283.72% Return on Equity-97.34% Return on Assets-63.64% Debt Debt-to-Equity Ratio0.12 Current Ratio3.71 Quick Ratio3.71 Sales & Book Value Annual Sales$2.07 million Price / Sales61.27 Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book1.04Miscellaneous Outstanding Shares55,140,000Free Float23,710,000Market Cap$126.82 million OptionableNot Optionable Beta0.74 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Mahesh Karande (Age 49)Pres, CEO & Board Director Comp: $812.88kMs. Ling Zeng Esq. (Age 54)J.D., Chief Legal & Admin. Officer and Sec. Comp: $519.36kDr. Yan Moore M.D. (Age 56)Chief Medical Officer Comp: $1.14MMr. Joshua Reed M.B.A. (Age 50)Chief Financial Officer Dr. Sivakesava Sakhamuri Ph.D.Sr. VP and Head of Technical Operations & QualityDr. Thomas McCauley (Age 54)Chief Scientific Officer Mr. Charles O'Donnell Ph.D.VP and Head of Computational Genomics & Data SciencesMs. Ramola BhandarkarSr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsINmune BioNASDAQ:INMBTScan TherapeuticsNASDAQ:TCRXTalaris TherapeuticsNASDAQ:TALSCentury TherapeuticsNASDAQ:IPSCSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 8,107 shares on 8/21/2023Ownership: 0.015%Goldman Sachs Group Inc.Sold 34,240 shares on 8/15/2023Ownership: 0.031%Citadel Advisors LLCBought 4,800 shares on 8/15/2023Ownership: 0.000%Wells Fargo & Company MNBought 10,019 shares on 8/15/2023Ownership: 0.018%Jefferies Financial Group Inc.Sold 15,000 shares on 8/14/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions OMGA Stock - Frequently Asked Questions Should I buy or sell Omega Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMGA shares. View OMGA analyst ratings or view top-rated stocks. What is Omega Therapeutics' stock price forecast for 2023? 4 analysts have issued 1 year price objectives for Omega Therapeutics' stock. Their OMGA share price forecasts range from $10.00 to $12.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 378.3% from the stock's current price. View analysts price targets for OMGA or view top-rated stocks among Wall Street analysts. How have OMGA shares performed in 2023? Omega Therapeutics' stock was trading at $5.71 on January 1st, 2023. Since then, OMGA shares have decreased by 59.7% and is now trading at $2.30. View the best growth stocks for 2023 here. When is Omega Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our OMGA earnings forecast. How were Omega Therapeutics' earnings last quarter? Omega Therapeutics, Inc. (NASDAQ:OMGA) released its earnings results on Thursday, August, 3rd. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.03. The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.63 million. Omega Therapeutics had a negative trailing twelve-month return on equity of 97.34% and a negative net margin of 4,283.72%. When did Omega Therapeutics IPO? (OMGA) raised $126 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. What is Omega Therapeutics' stock symbol? Omega Therapeutics trades on the NASDAQ under the ticker symbol "OMGA." Who are Omega Therapeutics' major shareholders? Omega Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.92%), Platinum Investment Management Ltd. (1.61%), 683 Capital Management LLC (0.86%), Geode Capital Management LLC (0.80%), State Street Corp (0.71%) and Northern Trust Corp (0.37%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young. View institutional ownership trends. How do I buy shares of Omega Therapeutics? Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Omega Therapeutics' stock price today? One share of OMGA stock can currently be purchased for approximately $2.30. How much money does Omega Therapeutics make? Omega Therapeutics (NASDAQ:OMGA) has a market capitalization of $126.82 million and generates $2.07 million in revenue each year. The company earns $-102,700,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. How many employees does Omega Therapeutics have? The company employs 116 workers across the globe. How can I contact Omega Therapeutics? Omega Therapeutics' mailing address is 20 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.omegatherapeutics.com. The company can be reached via phone at 617-949-4360 or via email at argotomega@argotpartners.com. This page (NASDAQ:OMGA) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.